NO324817B1 - Fremgangsmate for screening av stoffer som pavirker aktiviteten til FREAC 11 - Google Patents
Fremgangsmate for screening av stoffer som pavirker aktiviteten til FREAC 11 Download PDFInfo
- Publication number
- NO324817B1 NO324817B1 NO19995786A NO995786A NO324817B1 NO 324817 B1 NO324817 B1 NO 324817B1 NO 19995786 A NO19995786 A NO 19995786A NO 995786 A NO995786 A NO 995786A NO 324817 B1 NO324817 B1 NO 324817B1
- Authority
- NO
- Norway
- Prior art keywords
- freac
- gene
- lpl
- activity
- obesity
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 22
- 230000000694 effects Effects 0.000 title claims description 18
- 239000000126 substance Substances 0.000 title claims description 18
- 238000012216 screening Methods 0.000 title claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 10
- 101150062900 lpl gene Proteins 0.000 claims description 20
- 208000008589 Obesity Diseases 0.000 claims description 15
- 235000020824 obesity Nutrition 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000022531 anorexia Diseases 0.000 claims description 3
- 230000001925 catabolic effect Effects 0.000 claims description 3
- 206010061428 decreased appetite Diseases 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000001789 adipocyte Anatomy 0.000 abstract description 13
- 102000040945 Transcription factor Human genes 0.000 abstract description 10
- 108091023040 Transcription factor Proteins 0.000 abstract description 10
- 210000000577 adipose tissue Anatomy 0.000 abstract description 10
- 230000004069 differentiation Effects 0.000 abstract description 5
- 239000003596 drug target Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000004568 DNA-binding Effects 0.000 description 20
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 17
- 102000043296 Lipoprotein lipases Human genes 0.000 description 17
- 108700008625 Reporter Genes Proteins 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 101150028074 2 gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 101150014691 PPARA gene Proteins 0.000 description 3
- 230000011759 adipose tissue development Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 101150000874 11 gene Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003165 hybrid screening Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developing Agents For Electrophotography (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9701963A SE9701963D0 (sv) | 1997-05-26 | 1997-05-26 | Novel transcription factor |
| PCT/SE1998/000989 WO1998054216A1 (en) | 1997-05-26 | 1998-05-26 | Gene and amino acid sequences for novel transcription factor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO995786D0 NO995786D0 (no) | 1999-11-25 |
| NO995786L NO995786L (no) | 2000-01-25 |
| NO324817B1 true NO324817B1 (no) | 2007-12-10 |
Family
ID=20407085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19995786A NO324817B1 (no) | 1997-05-26 | 1999-11-25 | Fremgangsmate for screening av stoffer som pavirker aktiviteten til FREAC 11 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1003776B1 (sv) |
| JP (1) | JP2002503102A (sv) |
| AT (1) | ATE273321T1 (sv) |
| AU (1) | AU742500B2 (sv) |
| CA (1) | CA2291484A1 (sv) |
| DE (1) | DE69825594T2 (sv) |
| NO (1) | NO324817B1 (sv) |
| NZ (1) | NZ501804A (sv) |
| SE (1) | SE9701963D0 (sv) |
| WO (1) | WO1998054216A1 (sv) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE304552T1 (de) * | 2000-02-18 | 2005-09-15 | Leangene Ab | Methoden zur identifizierung von zusammensetzungen, die für die behandlung von fettleibigkeit nützlich sind, unter verwendung von foxc2 |
| WO2002027008A1 (en) * | 2000-09-26 | 2002-04-04 | Biovitrum Ab | Promoter sequences |
| EP1468017A1 (en) * | 2002-01-29 | 2004-10-20 | Biovitrum Ab | A complex of a human foxc2 protein and a foxc2-interacting protein |
| US7955795B2 (en) | 2003-06-06 | 2011-06-07 | Qiagen Gmbh | Method of whole genome amplification with reduced artifact production |
| WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
| EP1762627A1 (de) | 2005-09-09 | 2007-03-14 | Qiagen GmbH | Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563036A (en) * | 1994-04-29 | 1996-10-08 | Tularik, Inc. | Transcription factor-DNA binding assay |
-
1997
- 1997-05-26 SE SE9701963A patent/SE9701963D0/sv unknown
-
1998
- 1998-05-26 WO PCT/SE1998/000989 patent/WO1998054216A1/en active IP Right Grant
- 1998-05-26 CA CA002291484A patent/CA2291484A1/en not_active Abandoned
- 1998-05-26 AT AT98924724T patent/ATE273321T1/de not_active IP Right Cessation
- 1998-05-26 JP JP50058699A patent/JP2002503102A/ja not_active Ceased
- 1998-05-26 EP EP98924724A patent/EP1003776B1/en not_active Expired - Lifetime
- 1998-05-26 DE DE69825594T patent/DE69825594T2/de not_active Expired - Fee Related
- 1998-05-26 AU AU76826/98A patent/AU742500B2/en not_active Ceased
- 1998-05-26 NZ NZ501804A patent/NZ501804A/en unknown
-
1999
- 1999-11-25 NO NO19995786A patent/NO324817B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO995786D0 (no) | 1999-11-25 |
| AU7682698A (en) | 1998-12-30 |
| EP1003776A1 (en) | 2000-05-31 |
| CA2291484A1 (en) | 1998-12-03 |
| EP1003776B1 (en) | 2004-08-11 |
| NZ501804A (en) | 2002-06-28 |
| NO995786L (no) | 2000-01-25 |
| SE9701963D0 (sv) | 1997-05-26 |
| AU742500B2 (en) | 2002-01-03 |
| ATE273321T1 (de) | 2004-08-15 |
| DE69825594T2 (de) | 2005-09-15 |
| DE69825594D1 (de) | 2004-09-16 |
| WO1998054216A1 (en) | 1998-12-03 |
| JP2002503102A (ja) | 2002-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hood et al. | Unravelling the mechanisms regulating muscle mitochondrial biogenesis | |
| Wilde et al. | Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel | |
| Handschin et al. | PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy | |
| Sakaue et al. | Phosphoinositide 3-kinase is required for insulin-induced but not for growth hormone-or hyperosmolarity-induced glucose uptake in 3T3-L1 adipocytes | |
| Buitrago et al. | The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy | |
| Soriano et al. | Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator–activated receptor-γ coactivator-1α, estrogen-related receptor-α, and mitofusin 2 | |
| Depre et al. | H11 kinase is a novel mediator of myocardial hypertrophy in vivo | |
| Hogan et al. | The regulation of fatty acid synthase by STAT5A | |
| Hamaguchi et al. | Expression of the gene for Dec2, a basic helix–loop–helix transcription factor, is regulated by a molecular clock system | |
| Zanchi et al. | Glucocorticoids: extensive physiological actions modulated through multiple mechanisms of gene regulation | |
| Luo et al. | Fasting-induced protein phosphatase 1 regulatory subunit contributes to postprandial blood glucose homeostasis via regulation of hepatic glycogenesis | |
| Chen et al. | Transcription factor Ets-1 links glucotoxicity to pancreatic beta cell dysfunction through inhibiting PDX-1 expression in rodent models | |
| Gao et al. | Redox regulation, NF-κB, and atrial fibrillation | |
| Baker | Adrenal and sex steroid receptor evolution: environmental implications | |
| Nakagawa et al. | Class II HDACs mediate CaMK-dependent signaling to NRSF in ventricular myocytes | |
| Song et al. | Ligand-dependent corepressor acts as a novel corepressor of thyroid hormone receptor and represses hepatic lipogenesis in mice | |
| Mueller | Browning and graying: novel transcriptional regulators of brown and beige fat tissues and aging | |
| Ro et al. | Adipocyte enhancer‐binding protein 1 modulates adiposity and energy homeostasis | |
| Fluck et al. | SRF protein is upregulated during stretch-induced hypertrophy of rooster ALD muscle | |
| Gao et al. | Malonyl-CoA mediates leptin hypothalamic control of feeding independent of inhibition of CPT-1a | |
| Lu et al. | QKI regulates adipose tissue metabolism by acting as a brake on thermogenesis and promoting obesity | |
| Dahle et al. | Mechanisms of FOXC2-and FOXD1-mediated regulation of the RIα subunit of cAMP-dependent protein kinase include release of transcriptional repression and activation by protein kinase Bα and cAMP | |
| Chung et al. | Regulation of human resistin gene expression in cell systems: an important role of stimulatory protein 1 interaction with a common promoter polymorphic site | |
| NO324817B1 (no) | Fremgangsmate for screening av stoffer som pavirker aktiviteten til FREAC 11 | |
| Montminy et al. | The CREB family: key regulators of hepatic metabolism |